The role of diet in multiple sclerosis: A review

Nutritional Neuroscience

Volumn 21, Issue 6, 2018, Pages 377-390

  Esposito, Sabrina ^a,b   Bonavita, Simona ^a,c   Sparaco, Maddalena ^a   Gallo, Antonio ^a,c   Tedeschi, Gioacchino ^a,c  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Institute for Diagnosis and Care Hermitage Capodimonte   (Italy)

Author keywords

Diet; Dietary recommendation; Gut microbiota; Inflammation; Malnutrition; Multiple sclerosis; Nutrients in multiple sclerosis; Nutritional assessment

Indexed keywords

ANTIOXIDANT; BIOTIN; COBALAMIN; FAT; GAMMA TOCOPHEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEPTIN; LEPTIN RECEPTOR; LINOLEIC ACID; LIPOPOLYSACCHARIDE; OMEGA 3 FATTY ACID; RETINOIC ACID; SATURATED FATTY ACID; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NRF2; VITAMIN D; FATTY ACID; TRACE ELEMENT; UNSATURATED FATTY ACID;

ALLERGIC ENCEPHALOMYELITIS; ALTERNATIVE MEDICINE; BLADDER DYSFUNCTION; BODY COMPOSITION; CONTROLLED CLINICAL TRIAL (TOPIC); DECUBITUS; DIET SUPPLEMENTATION; DYSBIOSIS; GENE EXPRESSION; HUMAN; HYPERLEPTINEMIA; INFLAMMATION; INTESTINE FLORA; LIPID DIET; LOW FAT DIET; MALNUTRITION; MULTIPLE SCLEROSIS; NONHUMAN; NUTRITIONAL STATUS; OBESITY; OSTEOPOROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; WESTERN DIET; ANIMAL; BLOOD; DIET; DIETARY REFERENCE INTAKE; DISEASE MODEL;

ANIMALS; ANTIOXIDANTS; BODY COMPOSITION; COMPLEMENTARY THERAPIES; DIET; DISEASE MODELS, ANIMAL; DYSBIOSIS; FATTY ACIDS; FATTY ACIDS, UNSATURATED; HUMANS; INFLAMMATION; LEPTIN; LIPOPOLYSACCHARIDES; MALNUTRITION; MICRONUTRIENTS; MULTIPLE SCLEROSIS; NUTRITIONAL STATUS; OBESITY; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMMENDED DIETARY ALLOWANCES; RISK FACTORS; VITAMIN D;

EID: 85048278125     PISSN: 1028415X     EISSN: 14768305     Source Type: Journal    
DOI: 10.1080/1028415X.2017.1303016     Document Type: Review

References (189)

1. Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D. University of British Columbia MS Clinic Neurologists. Early onset multiple sclerosis: a longitudinal study. Neurology 2002;59(7):1006–10.
2. Alroughani R, Akhtar S, Ahmed S, Behbehani R, Al-Hashel J. Is time to reach EDSS 6.0 faster in patients with late-onset versus young-onset multiple sclerosis? PLoS One 2016;11(11):e0165846.
3. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol 2008;7(3):268–77.
4. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014;83(3):278–86.
5. Masullo L, Papas MA, Cotugna N, Baker S, Mahoney L, Trabulsi J. Complementary and alternative medicine use and nutrient intake among individuals with multiple sclerosis in the United States. J Community Health 2015;40(1):153–60.
6. Ontaneda D, Thompson AJ, Fox RJ, Cohen JA. Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet 2016. pii: S0140-6736(16)31320-4. doi:10.1016/S0140-6736(16)31320-4.
7. Schuh C, Wimmer I, Hametner S, Haider L, Van Dam AM, Liblau RS, et al. Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models. Acta Neuropathol 2014;128(2):247–66.
8. WHO and Multiple Sclerosis International Federation. Atlas: multiple sclerosis resources in the world 2008. Geneva, Switzerland: World Health Organisation.
9. Thompson AJ. Multiple sclerosis–a global disorder and still poorly managed. Lancet Neurol 2008;7(12):1078–9.
10. Swank RL, Lestad O, Strøm A, Backer J. Multiple sclerosis in rural Norway; its geographic and occupational incidence in relation to nutrition. N Engl J Med 1952;246:721–8.
11. Agranoff BW, Golberg D. Diet and the geographical distribution of multiple sclerosis. Lancet 1974;304:1061–6.
12. Alter M, Yamoor M, Harshe M. Multiple sclerosis and nutrition. Arch Neurol 1974;31:267–72.
13. Lauer K. The risk of multiple sclerosis in the USA in relation to sociogeographic features: a factor-analytic study. J Clin Epidemiol 1994;47:43–8.
14. Esparza ML, Sasaki S, Kesteloot H. Nutrition latitude and multiple sclerosis mortality: an ecologic study. Am J Epidemiol 1995;142:733–7.
15. Antonovsky A, Leibowitz U, Smith HA, Medalie JM, Balogh M, Kats R, et al. Epidemiologic study of multiple sclerosis in Israel. I. An overall review of methods and findings. Arch Neurol 1965;13:183–93.
16. Cendrowski W, Wender M, Dominik W, Flejsierowicz Z, Owsianowski M, Popiel M. Epidemiological study of multiple sclerosis in western Poland. Eur Neurol 1969;2:90–108.
17. Berr C, Puel J, Clanet M, Ruidavets JB, Mas JL, Alperovitch A. Risk factor in multiple sclerosis: a population-based case-control study in Hautes-Pyrenees, France. Acta Neurol Scand 1989;80:46–50.
18. Tola MR, Granieri E, Malagù S, Caniatti L, Casetta I, Govoni V, et al. Dietary habits and multiple sclerosis. A retrospective study in Ferrara, Italy. Acta Neurol (Napoli) 1994;16:189–97.
19. Zhang SM, Willett WC, Hernán MA, Olek MJ, Ascherio A. Dietary fat in relation to risk of multiple sclerosis among two large cohorts of women. Am J Epidemiol 2000;152:1056–64.
20. Sepcić J, Mesaros E, Materljan E, Sepić-Grahovac D. Nutritional factors and multiple sclerosis in Gorski Kotar, Croatia. Neurepidemiology 2004;12(4):234–40.
21. Ghadirian P, Jain M, Ducic S, Shatenstein B, Morisset R. Nutritional factors in the aetiology of multiple sclerosis: a case-control study in Montreal, Canada. Int J Epidemiol 1998;27:845–52.
22. Lauer K. Diet and multiple sclerosis. Neurology 1997;49:S55–61.
23. Harbige LS. Dietary n-6 and n-3 fatty acids in immunity and autoimmune disease. Proc Nutr Soc 1998;57(4):555–62.
24. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002;21(6):495–505.
25. Choi IY, Piccio L, Childress P, Bollman B, Ghosh A, Brandhorst S, et al. A diet mimicking fasting promotes regeneration and reduces autoimmunity and multiple sclerosis symptoms. Cell Rep. 2016;15(10):2136–46.
26. Dworkin RH, Bates D, Millar JH, Paty DW. Linoleic acid and multiple sclerosis: a reanalysis of three double-blind trials. Neurology 1984;34:1441–5.
27. Bates D, Cartlidge NE, French JM, Jackson MJ, Nightingale S, Shaw DA, et al. A double blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 1989;52(1):18–22.
28. Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-Kwen P, Gallagher E, et al. Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids 2005;73(5):397–404.
29. Torkildsen O, Wergeland S, Bakke S, Beiske AG, Bjerve KS, Hovdal H, et al. Ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. Arch Neurol 2012;69(8):1044–51.
30. Pantzaris MC, Loukaides GN, Ntzani EE, Patrikios IS. A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial. BMJ Open. 2013;3(4). pii: e002170. doi:10.1136/bmjopen-2012-002170.
31. Matarese G, Di Giacomo A, Sanna V, Lord GM, Howard JK, Di Tuoro A, et al. Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J Immunol 2001;166(10):5909–16.
32. Sanna V, Di Giacomo A, La Cava A, Lechler RI, Fontana S, Zappacosta S, et al. Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J Clin Invest 2003;111(2):241–50.
33. Matarese G, La Cava A, Sanna V, Lord GM, Lechler RI, Fontana S, et al. Balancing susceptibility to infection and autoimmunity: a role for leptin? Trends Immunol. 2002;23(4):182–7.
34. Matarese G, Carrieri PB, La Cava A, Perna F, Sanna V, De Rosa V, et al. Leptin increase in multiple sclerosis associates with reduced number of CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci U S A. 2005;102(14):5150–5.
35. Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine (metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002;110(8):1093–103.
36. Härle P, Straub RH. Leptin is a link between adipose tissue and inflammation. Ann N Y Acad Sci 2006;1069:454–62.
37. DiPaolo RJ, Glass DD, Bijwaard KE, Shevach EM. CD4 + CD25+ T cells prevent the development of organ-specific autoimmune disease by inhibiting the differentiation of autoreactive effector T cells. J Immunol 2005;175(11):7135–42.
38. Frisullo G, Mirabella M, Angelucci F, Caggiula M, Morosetti R, Sancricca C, et al. The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis. J Neuroimmunol 2007;192(1–2):174–83.
39. Matarese G, Procaccini C, De Rosa V. The intricate interface between immune and metabolic regulation: a role for leptin in the pathogenesis of multiple sclerosis? J Leukoc Biol 2008;84(4):893–9.
40. Mc Guire C, Prinz M, Beyaert R, van Loo G. Nuclear factor kappa B (NF-κB) in multiple sclerosis pathology. Trends Mol Med 2013;19(10):604–13.
41. Riccio P, Rossano R, Liuzzi GM. May diet and dietary supplements improve the wellness of multiple sclerosis patients?. A molecular approach. Autoimmune Dis. 2011;2010:249842.
42. Alatab S, Maghbooli Z, Hossein-Nezhad A, Khosrofar M, Mokhtari F. Cytokine profile, Foxp3 and nuclear factor-kB ligand levels in multiple sclerosis subtypes. Minerva Med 2011;102(6):461–8.
43. Stelmasiak Zl, Kozioł-Montewka M, Dobosz B, Rejdak K, Bartosik-Psujek H, Mitosek-Szewczyk K, et al. Interleukin-6 concentration in serum and cerebrospinal fluid in multiple sclerosis patients. Med Sci Monit 2000;6(6):1104–8.
44. Trentini A, Manfrinato MC, Castellazzi M, Tamborino C, Roversi G, Volta CA, et al. TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis. Mult Scler 2015;21(9):1121–30.
45. Mattsson N, Yaong M, Rosengren L, Blennow K, Månsson JE, Andersen O, et al. Elevated cerebrospinal fluid levels of prostaglandin E2 and 15-(S)-hydroxyeicosatetraenoic acid in multiple sclerosis. J Intern Med 2009;265(4):459–64.
46. Neu IS, Metzger G, Zschocke J, Zelezny R, Mayatepek E. Leukotrienes in patients with clinically active multiple sclerosis. Acta Neurol Scand 2002;105(1):63–6.
47. Pall ML, Levine S. Nrf2, a master regulator of detoxification and also antioxidant, anti-inflammatory and other cytoprotective mechanisms, is raised by health promoting factors. Sheng Li Xue Bao 2015;67(1):1–18.
48. Buelna-Chontal M, Zazueta C. Redox activation of Nrf2 and NF-κB: a double end sword?Cell Signal 2013;25(12):2548–57.
49. Pedruzzi LM, Stockler-Pinto MB, Leite M, Jr, Mafra D. Nrf2-keap1 system versus NF-κB: the good and the evil in chronic kidney disease?Biochimie 2012;94(12):2461–6.
50. Kim J, Cha YN, Surh YJ. A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutat Res 2010;690:12–23.
51. Becker J, Delayre-Orthez C, Frossard N, Pons F. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? Fundam Clin Pharmacol 2006;20:429–47.
52. Wang K, Wan YJ. Nuclear receptors and inflammatory diseases. Exp Biol Med (Maywood). 2008;233(5):496–506.
53. Riccio P, Rossano R. Nutrition facts in multiple sclerosis. ASN Neuro. 2015;7(1). pii: S0140-6736(16)31320-4. doi:10.1177/1759091414568185.
54. Hooper LV, Midtvedt T, Gordon JI. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr 2002;22:283–307.
55. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101(44):15718–23.
56. Bouskra D, Brézillon C, Bérard M, Werts C, Varona R, Boneca IG, et al. Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. Nature 2008;456(7221):507–10.
57. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell 2014;157(1):121–41.
58. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 2009;1:6ra14.
59. Panda S, Guarner F, Manichanh C. Structure and functions of the gut microbiome. Endocr Metab Immune Disord Drug Targets 2014;14(4):290–9.
60. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011;334(6052):105–8.
61. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2013;505(7484):559–63.
62. Brown K, DeCoffe D, Molcan E, Gibson DL. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients 2012;4(8):1095–119.
63. Guinane CM, Cotter PD. Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Therap Adv Gastroenterol 2013;6(4):295–308.
64. Cavalcante-Silva LH, Galvão JG, da Silva JS, de Sales-Neto JM, Rodrigues-Mascarenhas S. Obesitydriven gut microbiota inflammatory pathways to metabolic syndrome. Front Physiol 2015;6:782.
65. Mielcarz DW, Kasper LH. The gut microbiome in multiple sclerosis. Curr Treat Options Neurol 2015;17(4):938.
66. Eisenstein EM, Williams CB. The T(reg)/Th17 cell balance: a new paradigm for autoimmunity. Pediatr Res 2009;65(5 Pt 2):26R–31R.
67. Lochner M, Wang Z, Sparwasser T. The special relationship in the development and function of T helper 17 and regulatory T cells. Prog Mol Biol Transl Sci 2015;136:99–129.
68. Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012;489(7415):231–41.
69. Kanauchi O, Serizawa I, Araki Y, Suzuki A, Andoh A, Fujiyama Y, et al. Germinated barley foodstuff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment. J Gastroenterol 2003;38(2):134–41.
70. Brahe LK, Astrup A, Larsen LH. Is butyrate the link between diet, intestinal microbiota and obesity-related metabolic diseases? Obes Rev 2013;14(12):950–9.
71. Jhangi S, Gandhi R, Glanz B, Cook S, Nejad P, Ward D, et al. Increased archaea species and changes with therapy in gut microbiome of multiple sclerosis subjects (S24.001). Neurology, 2014;82(10 Suppl):S24. 001–S024. 001.
72. Bhargava P, Mowry EM. Gut microbiome and multiple sclerosis. Curr Neurol Neurosci Rep 2014;14:240.
73. Tremlett H, Fadrosh D, Lynch S, Hart J, Graves J, Lulu S, et al. Gut microbiome in early pediatric multiple sclerosis: a case-control study [Abstract]. Neurology 2015;84:no.14 Supplement P4.027 http://www.neurology.org/content/84/14_Supplement/P4.027.
74. Mowry E, Waubant E, Chehoud C, DeSantis T, Kuczynski J, Warrington J. Gut bacterial populations in multiple sclerosis and in health (P05.106). Neurology 2012;78:P05.106.
75. Joscelyn J, Kasper LH. Digesting the emerging role for the gut microbiome in central nervous system demyelination. Mult Scler 2014;20(12):1553–9.
76. Clemente-Postigo M, Queipo-Ortuño MI, Murri M, Boto-Ordoñez M, Perez-Martinez P, Andres-Lacueva C, et al. Endotoxin increase after fat overload is related to postprandial hypertriglyceridemia in morbidly obese patients. J Lipid Res 2012;53(5):973–8.
77. Erridge C, Attina T, Spickett CM, Webb DJ. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am. J. Clin. Nutr 2007;86(5):1286–92.
78. Laugerette F, Vors C, Géloën A, Chauvin MA, Soulage C, Lambert-Porcheron S, et al. Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation. J Nutr Biochem 2011;22(1):53–9.
79. Amar J, Burcelin R, Ruidavets JB, Cani PD, Fauvel J, Alessi MC, et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr 2008;87(5):1219–23.
80. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007;50:2374–83.
81. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444(7121):860–7.
82. Nanri A, Moore MA, Kono S. Impact of C-reactive protein on disease risk and its relation to dietary factors. Asian Pac J Cancer Prev 2007;8(2):167–77.
83. Pereira SS, Alvarez-Leite JI. Low-grade inflammation, obesity, and diabetes. Curr Obes Rep 2014;3(4):422–31.
84. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G, Oberhollenzer F, et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol 1999;34:1975–81.
85. Witjes JJ, van Raalte DH, Nieuwdorp M. About the gut microbiome as a pharmacological target in atherosclerosis. Eur J Pharmacol 2015;763(PtA):75–8.
86. Nagpal R, Kumar M, Yadav AK, Hemalatha R, Yadav H, Marotta F, et al. Gut microbiota in health and disease: an overview focused on metabolic inflammation. Benef Microbes 2016;7(2):181–94.
87. Chassaing B, Gewirtz AT. Gut microbiota, low-grade inflammation, and metabolic syndrome. Toxicol Pathol 2014;42(1):49–53.
88. Aronson KJ, Cleghorn G, Goldenberg E. Assistance arrangements and use of services among persons with multiple sclerosis and their caregivers. Disabil Rehabil 1996;18(7):354–61.
89. Payne A. Nutrition and diet in the clinical management of multiple sclerosis. J Hum Nutr Diet 2001;14(5):349–57.
90. Guan XL, Wang H, Huang HS, Meng L. Prevalence of dysphagia in multiple sclerosis: a systematic review and meta-analysis. Neurol Sci 2015;36(5):671–81.
91. Timmerman GM, Stuifbergin AK. Eating patterns in women with multiple sclerosis. J Neurosci Nurs 1999;31(3):152–8.
92. Hadgkiss EJ, Jelinek GA, Weiland TJ, Pereira NG, Marck CH, van der Meer DM. The association of diet with quality of life, disability, and relapse rate in an international sample of people with multiple sclerosis. Nutr Neurosci 2015;18(3):125–36.
93. Malosse D, Perron H, Sasco A, Seigneurin JM. Correlation between milk and dairy product consumption and multiple sclerosis prevalence: a worldwide study. Neuroepidemiology 2004;11(4–6):304–12.
94. Pekmezovic TD, Tepavcevic DBK, Mesaros ST, Basuroski IBD, Stojsavljevic NS, Drulovic JS, et al. Food and dietary patterns and multiple sclerosis: a case-control study in Belgrade (Serbia). Italian Journal of Public Health 2009;6:81–7.
95. Hadgkiss EJ, Jelinek GA, Weiland TJ, Pereira NG, Marck CH, van der Meer DM. Methodology of an international study of people with multiple sclerosis recruited through Web 2.0 platforms: demographics, lifestyle, and disease characteristics. Neurol Res Int 2013;2013:580596.
96. Kes VB, Cesarik M, Matovina LZ, Zavoreo I, Corić L, Drnasin S, et al. The role of complementary and alternative medicine in therapy of multiple sclerosis. Acta Clin Croat 2013;52(4):464–71.
97. Leong EM, Semple SJ, Angley M, Siebert W, Petkov J, McKinnon RA. Complementary and alternative medicines and dietary interventions in multiple sclerosis: what is being used in South Australia and why? Complement Ther Med 2009;17(4):216–23.
98. Swank RL. Treatment of multiple sclerosis with a low-fat diet. J Am Diet Assoc 1960;36:322–5.
99. Swank RL, Dugan BB. Effect of low saturated fat diet in early and late cases of multiple sclerosis. Lancet 1990;336:37–9.
100. Farinotti M, Vacchi L, Simi S, Di Pietrantonj C, Brait L, Filippini G. Dietary interventions for multiple sclerosis. Cochrane Database Syst Rev 2012;12:CD004192.
101. Schwarz S, Leweling H. Multiple sclerosis and nutrition. Mult Scler 2005;11(1):24–32.
102. Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. High frequency of adverse health behaviors in multiple sclerosis. Mult Scler 2009;15(1):105–13.
103. Pinhas-Hamiel O, Livne M, Harari G, Achiron A. Prevalence of overweight, obesity and metabolic syndrome components in multiple sclerosis patients with significant disability. Eur J Neurol 2015;22(9):1275–9.
104. Ranadive SM, Yan H, Weikert M, Lane AD, Linden MA, Baynard T, et al. Vascular dysfunction and physical activity in multiple sclerosis. Med Sci Sports Exerc 2012;44(2):238–43.
105. Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Cutter G, et al. A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Mult Scler 2015;21(3):318–31.
106. Tettey P, Simpson S, Jr, Taylor BV, van der Mei IA. Vascular comorbidities in the onset and progression of multiple sclerosis. J Neurol Sci 2014;347(1-2):23–33.
107. Ge KY, Chang SY. Definition and measurement of child malnutrition. Biomed Environ Sci 2001;14(4):283–91.
108. Sorgun MH, Yucesan C, Tegin C. Is malnutrition a problem for multiple sclerosis patients? J Clin Neurosci 2014;21(9):1603–5.
109. Williams CM, Lines CM, McKay EC. Iron and zinc status in multiple sclerosis patients with pressure sores. Eur J Clin Nutr 1988;42(4):321–8.
110. Slawta JN, Wilcox AR, McCubbin JA, Nalle DJ, Fox SD, Anderson G. Health behaviors, body composition, and coronary heart disease risk in women with multiple sclerosis. Arch Phys Med Rehabil 2003;84(12):1823–30.
111. Williams AE, Vietri JT, Isherwood G, Flor A. Symptoms and association with health outcomes in relapsing-remitting multiple sclerosis: results of a US patient survey. Mult Scler Int 2014;2014:203183.
112. Motl RW, McAuley E, Snook EM. Physical activity and multiple sclerosis: a meta-analysis. Mult Scler 2005;11(4):459–63.
113. Fogelholm M. Physical activity, fitness and fatness: relations to mortality, morbidity and disease risk factors. A systematic review. Obes Rev 2010;11(3):202–21.
114. Jick SS, Li L, Falcone GJ, Vassilev ZP, Wallander MA. Mortality of patients with multiple sclerosis: a cohort study in UK primary care. J Neurol 2014;261(8):1508–17.
115. Wens I, Dalgas U, Stenager E, Eijnde BO. Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis–a systematic review. Mult Scler 2013;19(12):1556–64.
116. Monzani A, Rapa A, Prodam F, Fuiano N, Diddi G, Petri A, et al. High discrepancy in abdominal obesity prevalence according to different waist circumference cut-offs and measurement methods in children: need for age-risk-weighted standardized cut-offs? PLoS One 2016;11(1):e0146579.
117. Aune D, Sen A, Norat T, Janszky I, Romundstad P, Tonstad S, et al. Body mass index, abdominal fatness and heart failure incidence and mortality: a systematic review and dose-response meta-analysis of prospective studies. Circulation 2016;133(7):639–49.
118. Marrie RA, Elliott L, Marriott J, Cossoy M, Blanchard J, Tennakoon A, et al. Dramatically changing rates and reasons for hospitalization in multiple sclerosis. Neurology 2014;83(10):929–37.
119. Montalcini T, Moraca M, Ferro Y, Romeo S, Serra S, Raso MG, et al. Nutritional parameters predicting pressure ulcers and short-term mortality in patients with minimal conscious state as a result of traumatic and non-traumatic acquired brain injury. J Transl Med 2015;13:345.
120. Cereda E, Klersy C, Andreola M, Pisati R, Schols JM, Caccialanza R, et al.; OligoElement Sore Trial (OEST) Study Group. Cost-effectiveness of a disease-specific oral nutritional support for pressure ulcer healing. Clin Nutr. 2017;36(1):246–52. doi:10.1016/j.clnu.2015.11.012.
121. Demarré L, Van Lancker A, Van Hecke A, Verhaeghe S, Grypdonck M, Lemey J, et al. The cost of prevention and treatment of pressure ulcers: a systematic review. Int J Nurs Stud 2015;52(11):1754–74.
122. Holroyd C, Cooper C, Dennison E. Epidemiology of osteoporosis. Best Pract Res Clin Endocrinol Metab 2008;22:671–85.
123. Gupta S, Ahsan I, Mahfooz N, Abdelhamid N, Ramanathan M, Weinstock-Guttman B. Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions. CNS Drugs 2014;28(8):731–42.
124. Peters BS, Verly E, Jr, Marchioni DM, Fisberg M, Martini LA. The influence of breakfast and dairy products on dietary calcium and vitamin D intake in postpubertal adolescents and young adults. J Hum Nutr Diet 2012;25(1):69–74.
125. Dobson R, Ramagopalan S, Giovannoni G. Bone health and multiple sclerosis. Mult Scler 2012;18(11):1522–8.
126. Dong G, Zhang N, Wu Z, Liu Y, Wang L. Multiple sclerosis increases fracture risk: a meta-analysis. Biomed Res Int 2015;2015:650138.
127. Wiesel PH, Norton C, Glickman S, Kamm MA. Pathophysiology and management of bowel dysfunction in multiple sclerosis. Eur J Gastroenterol Hepatol 2001;13(4):441–8.
128. Preziosi G, Emmanuel A. Neurogenic bowel dysfunction: pathophysiology, clinical manifestations and treatment. Expert Rev Gastroenterol Hepatol 2009;3(4):417–23.
129. Coggrave M, Norton C, Cody JD. Management of faecal incontinence and constipation in adults with central neurological diseases. Cochrane Database Syst Rev 2014;(1):CD002115.
130. Corcos J. A urological challenge: voiding dysfunction in multiple sclerosis. Can Urol Assoc J 2013;7(9–10 Suppl 4):181–2.
131. Kaplan SA, Dmochowski R, Cash BD, Kopp ZS, Berriman SJ, Khullar V. Systematic review of the relationship between bladder and bowel function: implications for patient management. Int J Clin Pract 2013;67(3):205–16.
132. Romańczuk W, Korczawski R. Chronic constipation: a cause of recurrent urinary tract infections. Turk J Pediatr 1993;35(3):181–8.
133. Hellerstein S, Linebarger JS. Voiding dysfunction in pediatric patients. Clin Pediatr (Phila). 2003;42(1):43–9.
134. Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002;125(Pt5):952–60.
135. Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database Syst Rev 2015;12:CD008772.
136. Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 2012;10:CD001321.
137. Detsky AS, McLaughlin JR, Baker JP, Johnston N, Whittaker S, Mendelson RA, et al. What is subjective global assessment of nutritional status? J Parenter Enteral Nutr 1987;11:8.
138. Kondrup J, Allison SP, Elia M, Vellas B, Plauth M,; Educational and Clinical Practice Committee, European Society of Parenteral and Enteral Nutrition (ESPEN). ESPEN guidelines for nutrition screening 2002. Clin Nutr 2003;22(4):415–21.
139. Rubenstein LZ, Harker JO, Salvà A, Guigoz Y, Vellas B. Screening for undernutrition in geriatric practice: developing the short-form mini-nutritional assessment (MNA-SF). J Gerontol A Biol Sci Med Sci 2001;56(6):M366–72.
140. Guigoz Y. The Mini Nutritional Assessment (MNA) review of the literature–What does it tell us? J Nutr Health Aging 2006;10(6):466–85.
141. British Association for Enteral and Parenteral Nutrition (BAPEN). The ‘MUST’ explanatory booklet. A guide to ‘Malnutrition Universal Screening Tool’ (‘MUST’) for adults; [cited Nov 2003]. Available from: http://www.bapen.org.uk/pdfs/must/must_explan.pdf.
142. Pasquinelli S, Solaro C. Nutritional assessment and malnutrition in multiple sclerosis. Neurol Sci 2008;29(Suppl 4):367–9.
143. Lee SY, Gallagher D. Assessment methods in human body composition. Curr Opin Clin Nutr Metab Care 2008;11(5):566–72.
144. Wendin K, Ekman S, Bülow M, Ekberg O, Johansson D, Rothenberg E, et al. Objective and quantitative definitions of modified food textures based on sensory and rheological methodology. Food Nutr Res 2010;54:5134–44. doi:10.3402/fnr.v54i0.5134.
145. Parsons EL, Stratton RJ, Cawood AL, Smith TR, Elia M. Oral nutritional supplements in a randomised trial are more effective than dietary advice at improving quality of life in malnourished care home residents. Clin Nutr 2016;36(1):134–42.
146. Scott R, Bowling TE. Enteral tube feeding in adults. J R Coll Physicians Edinb 2015;45(1):49–54.
147. Zalar AE, Guédon C, Piskorz EL, Sánchez Basso A, Ducrotté P. Percutaneous endoscopic gastrostomy in patients with neurological diseases. Results of a prospective multicenter and international study. Acta Gastroenterol Latinoam 2004;34(3):127–32.
148. Bourre JM. Roles of unsaturated fatty acids (especially omega-3 fatty acids) in the brain at various ages and during ageing. J Nutr Health Aging 2004;8(3):163–74.
149. WHO, FAO. Fats and fatty acids in human nutrition report of an expert consultation. Rome: Food and Agriculture organization of the United Nations; 2010.
150. Gallai V, Sarchielli P, Trequattrini A, Franceschini M, Floridi A, Firenze C, et al. Cytokine secretion and eicosanoid production in the peripheral blood mononuclear cells of MS patients undergoing dietary supplementation with n-3 polyunsaturated fatty acids. J Neuroimmunol 1995;56(2):143–53.
151. de Jong AJ, Kloppenburg M, Toes RE, Ioan-Facsinay A. Fatty acids, lipid mediators, and T-cell function. Front Immunol 2014;5:483.
152. Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood) 2008;233(6):674–88.
153. Schmitz G, Ecker J. The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res 2008;47(2):147–55.
154. Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004;292:1440–6.
155. Fedor D, Kelley DS. Prevention of insulin resistance by n-3 polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care 2009;12:138–46.
156. Gupta R, Lakshmy R, Abraham RA, Reddy KS, Jeemon P, Prabhakaran D, et al. Serum omega-6/omega-3 ratio and risk markers for cardiovascular disease in an industrial population of delhi. Food Nutr Sci 2013;4:94–7. http://dx.doi.org/10.4236/fns.2013.49A1015.
157. Riccio P, Rossano R, Larocca M, Trotta V, Mennella I, Vitaglione P, et al. Anti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: a pilot study. Exp Biol Med (Maywood). 2016;241(6):620–35.
158. Rosen CJ, Adams JS, Bikle DD, Black DM, Demay MB, Manson JE, et al. The nonskeletal effects of vitamin D: an endocrine society scientific statement. Endocr Rev 2012;33(3):456–92.
159. Hayes CE, Nashold FE, Spach KM, Pedersen LB. The immunological functions of the vitamin D endocrine system. Cell Mol Biol (Noisy-le grand) 2003;49(2):277–300.
160. Besusso D, Saul L, Leech MD, O'Connor RA, MacDonald AS, Anderton SM, et al. 1,25-Dihydroxyvitamin D3-conditioned CD11c+ dendritic cells are effective initiators of CNS autoimmune disease. Front Immunol 2015;6:233.
161. Lucas RM, Byrne SN, Correale J, Ilschner S, Hart PH. Ultraviolet radiation, vitamin D and multiple sclerosis. Neurodegener Dis Manag 2015;5(5):413–24.
162. Farinotti M, Simi S, Di Pietrantonj C, McDowell N, Brait L, Lupo D, et al. Dietary interventions for multiple sclerosis. Cochrane Database Syst Rev 2007;(1):CD004192.
163. Hussain AN, Alkhenizan AH, El Shaker M, Raef H, Gabr A. Increasing trends and significance of hypovitaminosis D: a population-based study in the Kingdom of Saudi Arabia. Arch Osteoporos 2014;9:6.
164. Adami S, Romagnoli E, Carnevale V, Scillitani A, Giusti A, Rossini M, et al. Guidelines on prevention and treatment of vitamin D deficiency. Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS). Reumatismo 2011;63(3):129–47.
165. Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington (DC): National Academies Press (US); 1998.
166. Weir DG, Scott JM. Brain function in the elderly: role of vitamin B12 and folate. Br Med Bull 1999;55(3):669–82.
167. 12, folate, and multiple sclerosis. J Clin Neurosci 2011;18(7):933–8.
168. Najafi MR, Shaygannajad V, Mirpourian M, Gholamrezaei A. Vitamin B(12) deficiency and multiple sclerosis; is there any association? Int J Prev Med 2012;3(4):286–9.
169. Sedel F, Papeix C, Bellanger A, Touitou V, Lebrun-Frenay C, Galanaud D, et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord 2015;4(2):159–69.
170. Peyro Saint Paul L, Debruyne D, Bernard D, Mock DM, Defer GL. Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis. Expert Opin Drug Metab Toxicol 2016;12(3):327–44.
171. Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. Washington, DC: National Academy Press; 2001. https://www.ncbi.nlm.nih.gov/books/NBK222310/.
172. WHO. Global prevalence of vitamin A deficiency in populations at risk 1995–2005. WHO global database on vitamin A deficiency. Geneva: World Health Organization; 2009.
173. Racke MK, Burnett D, Pak SH, Albert PS, Cannella B, Raine CS, et al. Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J Immunol. 1995;154:450.
174. + regulatory T cells and inhibits development of Th17 cells by enhancing TGF-β-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J Immunol. 2008;181(4):2455–64.
175. Bitarafan S, Saboor-Yaraghi A, Sahraian MA, Soltani D, Nafissi S, Togha M, et al. Effect of vitamin A supplementation on fatigue and depression in multiple sclerosis patients: a double-blind placebo-controlled clinical trial. Iran J Allergy Asthma Immunol. 2016;15(1):13–9.
176. Yasui M, Yase Y, Ando K, Adachi K, Mukoyama M, Ohsugi K. Magnesium concentration in brains from multiple sclerosis patients. Acta Neurol Scand 1990;81(3):197–200.
177. Johnson S. The possible role of gradual accumulation of copper, cadmium, lead and iron and gradual depletion of zinc, magnesium, selenium, vitamins B2, B6, D, and E and essential fatty acids in multiple sclerosis. Med Hypotheses 2000;55(3):239–41.
178. Haider L, Simeonidou C, Steinberger G, Hametner S, Grigoriadis N, Deretzi G, et al. Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. J Neurol Neurosurg Psychiatry 2014;85(12):1386–95.
179. Bitarafan S, Harirchian MH, Nafissi S, Sahraian MA, Togha M, Siassi F, et al. Dietary Intake of nutrients and its correlation with fatigue in multiple sclerosis patients. Iran J Neurol 2014;13(1):28–32.
180. Prasad AS. Impact of the discovery of human zinc deficiency on health. J Trace Elem Med Biol 2014;28(4):357–63.
181. de Baaij JH, Hoenderop JG, Bindels RJ. Magnesium in man: implications for health and disease. Physiol Rev 2015;95(1):1–46.
182. Solovyev ND. Importance of selenium and selenoprotein for brain function: from antioxidant protection to neuronal signalling. J Inorg Biochem 2015;153:1–12.
183. Ramsaransing GS, Mellema SA, De Keyser J. Dietary patterns in clinical subtypes of multiple sclerosis: an exploratory study. Nutr J 2009;8:345.
184. Combs GF, Jr. Selenium in global food systems. Br J Nutr 2001;85(5):517–47.
185. Volpe S.L. Magnesium in disease prevention and overall health. Adv Nutr 2013;4(3):378S–83S.
186. Haider L, Fischer MT, Frischer JM, Bauer J, Höftberger R, Botond G, et al. Oxidative damage in multiple sclerosis lesions. Brain 2011;134(Pt7):1914–24.
187. Hadžović-Džuvo A, Lepara O, Valjevac A, Avdagić N, Hasić S, Kiseljaković E, et al. Serum total antioxidant capacity in patients with multiple sclerosis. Bosn J Basic Med Sc 2011;11(1):33–6.
188. Plemel JR, Juzwik CA, Benson CA, Monks M, Harris C, Ploughman M. Over-the-counter anti-oxidant therapies for use in multiple sclerosis: a systematic review. Mult Scler 2015;21(12):1485–95.
189. Fürst R, Zündorf I. Plant-derived anti-inflammatory compounds: hopes and disappointments regarding the translation of preclinical knowledge into clinical progress. Mediators Inflamm 2014;2014:146832.